Skip to content
approvedHormone Regulation

Abarelix

Also known as: Plenaxis, Abarelix Depot-M

Abarelix was the first GnRH antagonist approved by the FDA for the treatment of advanced symptomatic prostate cancer in patients who refused surgical castration, were not candidates for GnRH agonists, or had impending complications where the testosterone flare from agonists was unacceptable. Marketed as Plenaxis, it achieved rapid testosterone suppression without flare by directly blocking pituitary GnRH receptors. However, due to a risk of immediate-onset systemic allergic reactions (including anaphylaxis in approximately 1.1% of patients), the FDA imposed strict prescribing restrictions and a mandatory 30-minute post-injection observation period. These safety concerns ultimately limited its commercial viability in the US, and it was voluntarily withdrawn from the American market, though it remained available in some international markets. It was largely superseded by degarelix (Firmagon), which has a more favorable safety profile.

3 cited references·4 researched benefits

Quick Answer

Abarelix (Plenaxis) was the first FDA-approved GnRH antagonist for advanced prostate cancer, achieving rapid testosterone suppression without the testosterone flare of GnRH agonists. However, a 1.1% risk of immediate-onset systemic allergic reactions including anaphylaxis led to strict prescribing restrictions and a mandatory 30-minute observation period. It was largely replaced by degarelix (Firmagon), which has a better safety profile.

Key Facts

Mechanism
Abarelix is a synthetic decapeptide that competitively antagonizes GnRH receptors on pituitary gonadotroph cells, immediately blocking the stimulatory effect of endogenous GnRH. Unlike GnRH agonists, it does not activate the receptor, so there is no initial LH/FSH surge and no testosterone flare. This produces rapid and direct suppression of gonadotropins, with castrate testosterone levels typically achieved within one week. After intramuscular injection, abarelix forms a depot that provides sustained drug release over approximately 2-4 weeks. The risk of allergic reactions is thought to be related to histamine release from the peptide structure, a property that has been mitigated in the newer antagonist degarelix.
Research Status
approved
Half-Life
~13 days (depot formulation)
Molecular Formula
C₇₂H₉₅ClN₁₄O₁₄
Primary Use
Hormone Regulation
Table of Contents

Benefits

  • No testosterone flare — achieves castrate levels within one week without the dangerous initial hormone surge of GnRH agonistsstrong
  • Rapid testosterone suppression — faster than GnRH agonists, critically important for patients with spinal cord compression or urinary obstruction at risk of flare complicationsstrong
  • No need for antiandrogen co-therapy — eliminates the need for antiandrogen flare protection and its associated side effectsstrong
  • Historical significance as the first GnRH antagonist approved for prostate cancer, demonstrating the clinical validity of the antagonist approachstrong

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intramuscular injection100 mgOn days 1, 15, and 29 (weeks 1, 2, and 4), then every 4 weeks thereafterMust be administered in a healthcare setting with 30-minute observation period after each injection due to anaphylaxis risk. Emergency resuscitation equipment must be immediately available. Only available through a restricted prescribing program in the US (when it was marketed).

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Immediate-onset systemic allergic reactions — occurred in 1.1% of patients, including anaphylaxis with hypotension, syncope, and urticaria; the primary safety concern that limited its useserious
  • Hot flashes — reported in approximately 75% of patients, the most common non-allergic adverse effectcommon
  • Injection site reactions — pain and discomfort at the intramuscular injection sitecommon
  • Sleep disturbances — insomnia reported in 15-20% of patientscommon
  • Breast enlargement (gynecomastia) and breast pain — reported in 5-10% of patientscommon
  • Decreased bone density — long-term risk associated with androgen deprivationserious
  • QT prolongation — risk of cardiac conduction abnormalities; ECG monitoring recommendedserious

Frequently Asked Questions

Why was abarelix withdrawn from the US market?
Abarelix (Plenaxis) was voluntarily withdrawn from the US market primarily due to commercial failure driven by its severe safety restrictions. The 1.1% risk of immediate-onset allergic reactions, including anaphylaxis, required: (1) administration only in a certified healthcare facility, (2) a mandatory 30-minute observation period after every injection, (3) immediate availability of emergency resuscitation equipment, and (4) enrollment in a restricted prescribing program. These requirements made it impractical for widespread use. When degarelix (Firmagon) was approved in 2008 with a better safety profile and no anaphylaxis risk, abarelix became essentially obsolete in the US.
How is abarelix different from degarelix?
Both are GnRH antagonists that block pituitary GnRH receptors without causing a testosterone flare. The critical difference is safety: abarelix had a 1.1% anaphylaxis risk requiring restrictive monitoring, while degarelix does not cause systemic allergic reactions. Abarelix is given intramuscularly, while degarelix is given subcutaneously. Degarelix has a longer effective half-life (~53 days vs. ~13 days for abarelix) and demonstrated superior PSA suppression in some analyses. Degarelix's injection site reactions, while common, are local and non-life-threatening. Degarelix has largely replaced abarelix worldwide.
Is abarelix still available anywhere?
While abarelix was withdrawn from the US market, it has remained available in some international markets, particularly in Germany and other European countries, where it is marketed as Abarelix Depot-M. International availability may vary and can change over time. For most practical purposes, degarelix has replaced abarelix as the GnRH antagonist of choice for prostate cancer worldwide due to its superior safety profile.
What did abarelix teach us about GnRH antagonist development?
Abarelix proved the concept that GnRH antagonists could achieve rapid castrate testosterone levels without flare, validating an important alternative to GnRH agonists. However, its allergic reaction profile highlighted the importance of histamine-related toxicity in peptide drug development. The lessons from abarelix directly informed the design of degarelix, which was engineered to minimize histamine release. Abarelix also demonstrated the commercial importance of a clean safety profile — even a small risk of serious adverse events, when it requires burdensome monitoring requirements, can make a drug commercially unviable.
Who was abarelix prescribed for when it was available?
Due to its restrictions, abarelix was reserved for a narrow patient population: men with advanced symptomatic prostate cancer who (1) could not receive a GnRH agonist due to unacceptable flare risk (e.g., impending spinal cord compression, severe urinary obstruction, extensive bone metastases), (2) refused surgical orchiectomy, and (3) did not have other adequate treatment options. It was essentially a "last resort" GnRH-based therapy. The FDA label carried a black box warning about the anaphylaxis risk. Very few patients were treated with abarelix before degarelix became available.

References

  1. 1
    Abarelix depot versus leuprolide plus daily antiandrogen for prostate cancer: a Phase 3 randomized trial(2004)PubMed ↗
  2. 2
    Abarelix, a GnRH antagonist, for the treatment of prostate cancer: pharmacology and clinical efficacy(2004)PubMed ↗
  3. 3
    Immediate-onset systemic allergic reactions with abarelix: post-marketing safety analysis(2005)PubMed ↗

Latest Research

Last updated: 2026-02-19